Talphera Advances NEFRO Phase 2 Enrollment, Reports 18% Q1 R&D Spend Rise
In Q1 2026 Talphera advanced its NEFRO Phase 2 trial into dose‐expansion, enrolling its third patient cohort and targeting completion of 60 patients by mid‐year. R&D spending rose 18% to $4.2 million as the company ramps clinical activities, with topline NEFRO data expected in H2 2026.
1. Q1 2026 Earnings Call Highlights
Talphera reported no revenue for Q1 2026 and logged an 18% increase in R&D expenses to $4.2 million, driven by expansion of its lead NEFRO clinical program. General and administrative costs remained flat, while the company reaffirmed no near‐term debt maturities.
2. NEFRO Study Progress
The NEFRO Phase 2 trial moved into its dose‐expansion phase during Q1 with completion of the third patient cohort. Management confirmed enrollment of 60 patients is on track by mid-2026 and expects to report topline efficacy and safety data in the second half of the year.
3. Financial Outlook and Cash Runway
With the accelerated NEFRO timeline, Talphera estimates its existing cash balance will fund operations into early 2027. The company is evaluating non-dilutive financing options to support subsequent Phase 3 preparations without impacting shareholder equity.